| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 16 | 2017 | 331 | 2.960 |
Why?
|
| Pleural Neoplasms | 9 | 2016 | 200 | 1.840 |
Why?
|
| Lung Neoplasms | 23 | 2017 | 2363 | 1.600 |
Why?
|
| Graft Rejection | 9 | 2017 | 1123 | 1.310 |
Why?
|
| Immunohistochemistry | 12 | 2017 | 1786 | 1.010 |
Why?
|
| Lung | 10 | 2017 | 1359 | 0.880 |
Why?
|
| Heart Transplantation | 8 | 2017 | 814 | 0.870 |
Why?
|
| Complement C4b | 2 | 2017 | 33 | 0.800 |
Why?
|
| Proto-Oncogene Proteins c-met | 8 | 2014 | 199 | 0.770 |
Why?
|
| Biomarkers, Tumor | 12 | 2017 | 1660 | 0.730 |
Why?
|
| Adenocarcinoma | 8 | 2017 | 1171 | 0.710 |
Why?
|
| Lung Transplantation | 3 | 2016 | 367 | 0.660 |
Why?
|
| Diagnosis, Differential | 11 | 2017 | 1519 | 0.650 |
Why?
|
| Myocardium | 5 | 2017 | 567 | 0.590 |
Why?
|
| Hypertension, Pulmonary | 7 | 2017 | 368 | 0.590 |
Why?
|
| Paxillin | 4 | 2013 | 59 | 0.560 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2013 | 1130 | 0.520 |
Why?
|
| Epithelium | 3 | 2015 | 314 | 0.500 |
Why?
|
| Pleura | 2 | 2013 | 30 | 0.490 |
Why?
|
| Forecasting | 1 | 2017 | 288 | 0.490 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2015 | 11 | 0.460 |
Why?
|
| Epoprostenol | 2 | 2012 | 46 | 0.450 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 90 | 0.450 |
Why?
|
| Fibrosis | 3 | 2017 | 228 | 0.420 |
Why?
|
| Pleurisy | 1 | 2013 | 4 | 0.410 |
Why?
|
| PAX5 Transcription Factor | 2 | 2010 | 33 | 0.400 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2013 | 46 | 0.400 |
Why?
|
| Hyperplasia | 1 | 2013 | 146 | 0.400 |
Why?
|
| Humans | 73 | 2018 | 93138 | 0.390 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2012 | 29 | 0.370 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 38 | 0.360 |
Why?
|
| Sarcoma | 1 | 2013 | 220 | 0.360 |
Why?
|
| Pulmonary Medicine | 1 | 2012 | 51 | 0.360 |
Why?
|
| Connective Tissue Diseases | 1 | 2012 | 75 | 0.350 |
Why?
|
| Postoperative Complications | 4 | 2016 | 2552 | 0.340 |
Why?
|
| Biopsy | 8 | 2017 | 1172 | 0.310 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2013 | 129 | 0.310 |
Why?
|
| Pathology, Surgical | 1 | 2009 | 13 | 0.300 |
Why?
|
| Prognosis | 8 | 2017 | 3891 | 0.290 |
Why?
|
| Lymphangiogenesis | 1 | 2008 | 42 | 0.280 |
Why?
|
| Neuroendocrine Tumors | 1 | 2010 | 136 | 0.280 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 505 | 0.270 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 183 | 0.270 |
Why?
|
| Middle Aged | 26 | 2018 | 27540 | 0.260 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 619 | 0.250 |
Why?
|
| Lung Diseases | 1 | 2009 | 282 | 0.250 |
Why?
|
| Cell Proliferation | 11 | 2014 | 1732 | 0.250 |
Why?
|
| Alveolitis, Extrinsic Allergic | 2 | 2017 | 43 | 0.240 |
Why?
|
| Antibodies | 1 | 2008 | 346 | 0.240 |
Why?
|
| Male | 34 | 2018 | 44357 | 0.240 |
Why?
|
| Peptide Fragments | 1 | 2008 | 468 | 0.240 |
Why?
|
| Retrospective Studies | 9 | 2018 | 10132 | 0.230 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2016 | 66 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2017 | 2562 | 0.230 |
Why?
|
| Epithelioid Cells | 2 | 2016 | 13 | 0.230 |
Why?
|
| Female | 32 | 2018 | 48544 | 0.220 |
Why?
|
| Adult | 19 | 2018 | 27850 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 298 | 0.200 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2018 | 284 | 0.200 |
Why?
|
| Aged | 18 | 2018 | 20399 | 0.190 |
Why?
|
| Receptor, EphB4 | 2 | 2013 | 23 | 0.190 |
Why?
|
| International Cooperation | 2 | 2013 | 132 | 0.190 |
Why?
|
| Aged, 80 and over | 10 | 2016 | 7039 | 0.190 |
Why?
|
| Tissue Array Analysis | 5 | 2016 | 134 | 0.180 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2013 | 156 | 0.180 |
Why?
|
| Cell Line, Tumor | 12 | 2016 | 2757 | 0.170 |
Why?
|
| S100 Proteins | 2 | 2012 | 51 | 0.170 |
Why?
|
| Cardiomyopathies | 2 | 2015 | 300 | 0.170 |
Why?
|
| Focal Adhesions | 2 | 2013 | 66 | 0.170 |
Why?
|
| Endothelium | 2 | 2013 | 59 | 0.160 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2012 | 232 | 0.160 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2010 | 18 | 0.160 |
Why?
|
| Mitochondria | 2 | 2016 | 612 | 0.160 |
Why?
|
| Asthma | 3 | 2013 | 1039 | 0.160 |
Why?
|
| Receptors, Lysosphingolipid | 2 | 2010 | 38 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 1060 | 0.150 |
Why?
|
| Phosphorylation | 6 | 2014 | 1129 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 360 | 0.150 |
Why?
|
| Indoles | 4 | 2013 | 298 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 3815 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2017 | 1518 | 0.140 |
Why?
|
| Apoptosis | 7 | 2014 | 1719 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2013 | 376 | 0.140 |
Why?
|
| Autopsy | 3 | 2013 | 126 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2013 | 603 | 0.140 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2016 | 37 | 0.140 |
Why?
|
| Antihypertensive Agents | 2 | 2010 | 256 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 889 | 0.130 |
Why?
|
| Pneumonectomy | 2 | 2016 | 217 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2017 | 47 | 0.130 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2017 | 210 | 0.130 |
Why?
|
| Public Opinion | 1 | 2017 | 50 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2013 | 1339 | 0.130 |
Why?
|
| Defibrillators, Implantable | 2 | 2016 | 186 | 0.120 |
Why?
|
| Kidney Neoplasms | 2 | 2014 | 531 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 11 | 0.120 |
Why?
|
| Allografts | 1 | 2017 | 205 | 0.120 |
Why?
|
| Gene Dosage | 6 | 2013 | 211 | 0.120 |
Why?
|
| Orbital Myositis | 1 | 2016 | 2 | 0.120 |
Why?
|
| Cytokines | 2 | 2012 | 862 | 0.120 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2013 | 23 | 0.120 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 71 | 0.120 |
Why?
|
| Fractals | 1 | 2016 | 41 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 1910 | 0.120 |
Why?
|
| Transplantation, Homologous | 2 | 2016 | 1014 | 0.120 |
Why?
|
| Niacinamide | 2 | 2013 | 101 | 0.120 |
Why?
|
| Paired Box Transcription Factors | 2 | 2013 | 50 | 0.120 |
Why?
|
| Myocarditis | 1 | 2016 | 59 | 0.110 |
Why?
|
| Primary Graft Dysfunction | 1 | 2016 | 44 | 0.110 |
Why?
|
| Genes, Dominant | 1 | 2015 | 111 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 214 | 0.110 |
Why?
|
| Consensus | 1 | 2017 | 366 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2015 | 65 | 0.110 |
Why?
|
| Carcinoma | 3 | 2013 | 439 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 255 | 0.110 |
Why?
|
| Toxoplasmosis | 1 | 2015 | 68 | 0.110 |
Why?
|
| Bronchoscopy | 2 | 2013 | 175 | 0.110 |
Why?
|
| Mice | 13 | 2015 | 12224 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2016 | 219 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 323 | 0.110 |
Why?
|
| Disease Models, Animal | 6 | 2013 | 2479 | 0.110 |
Why?
|
| RNA, Small Interfering | 4 | 2013 | 556 | 0.110 |
Why?
|
| Carbonic Anhydrases | 1 | 2014 | 14 | 0.100 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2014 | 15 | 0.100 |
Why?
|
| Survival Rate | 2 | 2016 | 1945 | 0.100 |
Why?
|
| Staphylococcal Infections | 2 | 2008 | 284 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 875 | 0.100 |
Why?
|
| Cell Cycle | 2 | 2014 | 515 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2015 | 222 | 0.100 |
Why?
|
| GATA3 Transcription Factor | 1 | 2013 | 52 | 0.100 |
Why?
|
| Indazoles | 1 | 2013 | 58 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 236 | 0.100 |
Why?
|
| Pulmonary Artery | 2 | 2017 | 333 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 2301 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 115 | 0.100 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 59 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 77 | 0.090 |
Why?
|
| Gene Expression | 2 | 2013 | 1304 | 0.090 |
Why?
|
| Hospitalization | 1 | 2018 | 925 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 191 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 174 | 0.090 |
Why?
|
| Lymphatic Vessels | 1 | 2013 | 70 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 356 | 0.090 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 154 | 0.090 |
Why?
|
| Bronchi | 1 | 2013 | 224 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2012 | 467 | 0.090 |
Why?
|
| Amyloidosis | 1 | 2014 | 132 | 0.090 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2012 | 22 | 0.090 |
Why?
|
| Cell Survival | 5 | 2013 | 1002 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2014 | 526 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2013 | 1517 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 2009 | 0.090 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2012 | 62 | 0.090 |
Why?
|
| Schools, Medical | 1 | 2013 | 131 | 0.090 |
Why?
|
| Animals | 16 | 2015 | 27965 | 0.090 |
Why?
|
| Piperazines | 3 | 2013 | 284 | 0.090 |
Why?
|
| Immunoblotting | 4 | 2012 | 273 | 0.080 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 31 | 0.080 |
Why?
|
| Plasma Exchange | 1 | 2011 | 28 | 0.080 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2012 | 97 | 0.080 |
Why?
|
| Hypocalcemia | 1 | 2011 | 43 | 0.080 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.080 |
Why?
|
| Sulfonamides | 3 | 2013 | 331 | 0.080 |
Why?
|
| Mutation | 7 | 2013 | 4265 | 0.080 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 64 | 0.080 |
Why?
|
| Vasodilation | 1 | 2010 | 91 | 0.080 |
Why?
|
| Urothelium | 1 | 2011 | 67 | 0.080 |
Why?
|
| Receptor, EphA2 | 1 | 2010 | 5 | 0.080 |
Why?
|
| Mitochondria, Muscle | 1 | 2010 | 24 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 357 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2013 | 2787 | 0.080 |
Why?
|
| Fatal Outcome | 4 | 2016 | 292 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2012 | 1073 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 1 | 2012 | 151 | 0.080 |
Why?
|
| Azathioprine | 1 | 2010 | 122 | 0.080 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 136 | 0.080 |
Why?
|
| Education, Medical | 1 | 2013 | 227 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 343 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 276 | 0.080 |
Why?
|
| Simvastatin | 1 | 2010 | 106 | 0.080 |
Why?
|
| Blood-Air Barrier | 1 | 2009 | 6 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2011 | 228 | 0.080 |
Why?
|
| Lung Injury | 1 | 2010 | 59 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2013 | 351 | 0.080 |
Why?
|
| Hemosiderosis | 1 | 2009 | 3 | 0.080 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2009 | 4 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 155 | 0.080 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 50 | 0.070 |
Why?
|
| Sirolimus | 1 | 2010 | 176 | 0.070 |
Why?
|
| Calcinosis | 1 | 2010 | 219 | 0.070 |
Why?
|
| Tacrolimus | 1 | 2010 | 372 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2011 | 555 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2010 | 156 | 0.070 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2008 | 4 | 0.070 |
Why?
|
| Islets of Langerhans | 1 | 2012 | 556 | 0.070 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 47 | 0.070 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2008 | 11 | 0.070 |
Why?
|
| Biomarkers | 3 | 2012 | 1905 | 0.070 |
Why?
|
| Skull Neoplasms | 1 | 2008 | 25 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2011 | 257 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2010 | 273 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 78 | 0.070 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2008 | 9 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 6 | 2012 | 3430 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2012 | 3781 | 0.070 |
Why?
|
| Cell Movement | 4 | 2014 | 804 | 0.070 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 70 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2015 | 321 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 441 | 0.070 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 70 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2008 | 67 | 0.070 |
Why?
|
| Temporal Bone | 1 | 2008 | 61 | 0.070 |
Why?
|
| Ventilators, Mechanical | 1 | 2008 | 43 | 0.070 |
Why?
|
| Disease Progression | 2 | 2012 | 1529 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 98 | 0.070 |
Why?
|
| Staphylococcus aureus | 2 | 2008 | 284 | 0.070 |
Why?
|
| Community-Acquired Infections | 1 | 2008 | 65 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 392 | 0.070 |
Why?
|
| Signal Transduction | 7 | 2013 | 3497 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2013 | 691 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 49 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 112 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 1980 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 287 | 0.070 |
Why?
|
| Hemodynamics | 2 | 2008 | 712 | 0.070 |
Why?
|
| Endocardium | 1 | 2008 | 79 | 0.070 |
Why?
|
| Coronary Circulation | 1 | 2008 | 95 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2008 | 260 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2016 | 4546 | 0.070 |
Why?
|
| Skin Diseases | 1 | 2009 | 173 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2008 | 155 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 537 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 364 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 958 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 391 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2011 | 403 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 184 | 0.060 |
Why?
|
| Alleles | 1 | 2010 | 1139 | 0.060 |
Why?
|
| Receptors, Complement 3d | 1 | 2006 | 14 | 0.060 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2006 | 20 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2011 | 1004 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 393 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 409 | 0.060 |
Why?
|
| Pyridines | 1 | 2008 | 302 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2007 | 311 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2016 | 9074 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 2465 | 0.060 |
Why?
|
| Waterhouse-Friderichsen Syndrome | 1 | 2005 | 1 | 0.060 |
Why?
|
| Ribs | 1 | 2006 | 48 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 987 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1055 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 59 | 0.060 |
Why?
|
| Algorithms | 1 | 2013 | 1948 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2006 | 69 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 985 | 0.050 |
Why?
|
| Quinazolines | 1 | 2006 | 211 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 740 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 2705 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2014 | 313 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 308 | 0.050 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2003 | 8 | 0.050 |
Why?
|
| Prevalence | 2 | 2017 | 1318 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2006 | 504 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 1578 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1385 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2485 | 0.040 |
Why?
|
| Genomics | 1 | 2008 | 848 | 0.040 |
Why?
|
| S100A12 Protein | 2 | 2012 | 10 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 2015 | 279 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2013 | 33 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2014 | 823 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2012 | 296 | 0.040 |
Why?
|
| Wound Healing | 2 | 2014 | 372 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 281 | 0.040 |
Why?
|
| Cisplatin | 2 | 2016 | 567 | 0.040 |
Why?
|
| Neoplasms | 2 | 2013 | 3169 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2013 | 672 | 0.040 |
Why?
|
| Genes, erbB-1 | 2 | 2010 | 15 | 0.040 |
Why?
|
| Chicago | 2 | 2017 | 1452 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2013 | 291 | 0.040 |
Why?
|
| Rats | 3 | 2010 | 4028 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 877 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2010 | 543 | 0.030 |
Why?
|
| Time Factors | 3 | 2011 | 5379 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 178 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2010 | 570 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 271 | 0.030 |
Why?
|
| Phenotype | 2 | 2016 | 2545 | 0.030 |
Why?
|
| Gene Silencing | 2 | 2009 | 177 | 0.030 |
Why?
|
| Infant | 3 | 2012 | 3156 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2827 | 0.030 |
Why?
|
| Radiography | 2 | 2012 | 750 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 228 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1908 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 106 | 0.030 |
Why?
|
| Atovaquone | 1 | 2015 | 3 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 570 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 128 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 186 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 360 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2010 | 2121 | 0.030 |
Why?
|
| Listeriosis | 1 | 2015 | 90 | 0.030 |
Why?
|
| Listeria monocytogenes | 1 | 2015 | 97 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 2014 | 15 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 126 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 85 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1241 | 0.030 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2014 | 11 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 941 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 177 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 448 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 512 | 0.030 |
Why?
|
| Shock, Cardiogenic | 1 | 2016 | 168 | 0.030 |
Why?
|
| Quinolines | 1 | 2014 | 85 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 98 | 0.030 |
Why?
|
| Prealbumin | 1 | 2014 | 45 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 138 | 0.030 |
Why?
|
| Transplantation Tolerance | 1 | 2015 | 143 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 451 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 147 | 0.020 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2013 | 29 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2016 | 499 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 87 | 0.020 |
Why?
|
| Amyloid | 1 | 2014 | 104 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 1003 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 1188 | 0.020 |
Why?
|
| Camptothecin | 1 | 2013 | 195 | 0.020 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2012 | 20 | 0.020 |
Why?
|
| Pancreatic Hormones | 1 | 2012 | 16 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2012 | 29 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2015 | 378 | 0.020 |
Why?
|
| Pancreas, Exocrine | 1 | 2012 | 18 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2012 | 77 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 121 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 37 | 0.020 |
Why?
|
| China | 1 | 2013 | 264 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 195 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1704 | 0.020 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 94 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 291 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2014 | 382 | 0.020 |
Why?
|
| Echocardiography | 1 | 2016 | 748 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 306 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2012 | 139 | 0.020 |
Why?
|
| Graft Survival | 1 | 2015 | 939 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 478 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 317 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 151 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 696 | 0.020 |
Why?
|
| Papilloma | 1 | 2011 | 23 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2011 | 87 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2010 | 64 | 0.020 |
Why?
|
| Rats, Mutant Strains | 1 | 2010 | 23 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2011 | 86 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2010 | 27 | 0.020 |
Why?
|
| New York City | 1 | 2010 | 69 | 0.020 |
Why?
|
| Biomimetics | 1 | 2010 | 28 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 40 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2010 | 23 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 653 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2012 | 293 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 1994 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 85 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 77 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 347 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2009 | 3 | 0.020 |
Why?
|
| ras Proteins | 1 | 2010 | 132 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 727 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2009 | 20 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 164 | 0.020 |
Why?
|
| Body Fluids | 1 | 2009 | 35 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 133 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2434 | 0.020 |
Why?
|
| Thiophenes | 1 | 2009 | 44 | 0.020 |
Why?
|
| Oxadiazoles | 1 | 2009 | 37 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 191 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 177 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 204 | 0.020 |
Why?
|
| Exercise Test | 1 | 2010 | 151 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 340 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1160 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2008 | 19 | 0.020 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2009 | 33 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2008 | 13 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 9550 | 0.020 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 68 | 0.020 |
Why?
|
| Leukocidins | 1 | 2008 | 3 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2008 | 61 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 40 | 0.020 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2008 | 5 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Chemokine CXCL2 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Exotoxins | 1 | 2008 | 21 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 620 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2008 | 39 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2008 | 86 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 753 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2009 | 351 | 0.020 |
Why?
|
| Rats, Inbred Dahl | 1 | 2008 | 7 | 0.020 |
Why?
|
| Complement C1q | 1 | 2008 | 12 | 0.020 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2008 | 12 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 254 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 590 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2008 | 133 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 300 | 0.020 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2008 | 31 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2008 | 66 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2011 | 355 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 78 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2008 | 113 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2007 | 65 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 97 | 0.020 |
Why?
|
| Virulence | 1 | 2008 | 273 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 1236 | 0.020 |
Why?
|
| Students, Medical | 1 | 2013 | 433 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 359 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2010 | 679 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 216 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 663 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 276 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 476 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 379 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 203 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 601 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 774 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1173 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 2427 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 1049 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 810 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 885 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 5901 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 2458 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1926 | 0.010 |
Why?
|
| Adrenal Gland Diseases | 1 | 2005 | 9 | 0.010 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2006 | 86 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 1866 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 2005 | 72 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 1114 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2007 | 360 | 0.010 |
Why?
|
| United States | 1 | 2018 | 7581 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 688 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1910 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1447 | 0.010 |
Why?
|
| Quality of Life | 1 | 2012 | 1776 | 0.010 |
Why?
|
| Neurons | 1 | 2012 | 1567 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2008 | 649 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2005 | 289 | 0.010 |
Why?
|
| Child | 1 | 2012 | 7273 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 6922 | 0.010 |
Why?
|